Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: A complex relationship

Cédric Dananche1,2*, Christelle Elias1,2, Laetitia Hénaff2, Séllah Amour1, Elisabetta Kuczewski1, Marie-Paule Gustin2, Vanessa Escuret3,4, Mitra Saadatian-Elahi1,2, Philippe Vanhems1,2

1 Service Hygiène, Épidémiologie, Infectiovigilance et Prévention, Hospices Civils de Lyon, Lyon, France, 2 Team « Public Health, Epidemiology and Evolutionary Ecology of Infectious Diseases (PHE3ID) », Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France, 3 Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France, 4 VirPath, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France

* cedric.dananche@chu-lyon.fr

Abstract

Introduction

Delay between symptom onset and access to care is essential to prevent clinical worsening for different infectious diseases. For COVID-19, this delay might be associated with the clinical prognosis, but also with the different characteristics of patients. The objective was to describe characteristics and symptoms of community-acquired (CA) COVID-19 patients at hospital admission according to the delay between symptom onset and hospital admission, and to identify determinants associated with delay of admission.

Methods

The present work was based on prospective NOSO-COR cohort data, and restricted to patients with laboratory confirmed CA SARS-CoV-2 infection admitted to Lyon hospitals between February 8 and June 30, 2020. Long delay of hospital admission was defined as ≥6 days between symptom onset and hospital admission. Determinants of the delay between symptom onset and hospital admission were identified by univariate and multiple logistic regression analysis.

Results

Data from 827 patients were analysed. Patients with a long delay between symptom onset and hospital admission were younger (p<0.01), had higher body mass index (p<0.01), and were more frequently admitted to intensive care unit (p<0.01). Their plasma levels of C-reactive protein were also significantly higher (p<0.01). The crude in-hospital fatality rate was lower in this group (13.3% versus 27.6%), p<0.01. Multiple analysis with correction for multiple testing showed that age ≥75 years was associated with a short delay between symptom
onset and hospital admission (≤5 days) (aOR: 0.47 95% CI (0.34–0.66)) and CRP>100 mg/L at admission was associated with a long delay (aOR: 1.84 95% CI (1.32–2.55)).

Discussion
Delay between symptom onset and hospital admission is a major issue regarding prognosis of COVID-19 but can be related to multiple factors such as individual characteristics, organization of care and severe pathogenic processes. Age seems to play a key role in the delay of access to care and the disease prognosis.

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogenic agent of coronavirus disease 2019 (COVID-19), is a new coronavirus that emerged from China in December 2019 [1]. The virus causes infections of the lower or upper respiratory tract of varying severity, from the common cold to severe pneumonia, respiratory failure, and death [2]. Male sex, old age, obesity, biological parameters such as biomarkers of inflammation, are known to be associated with severe disease [3–6]. The presence of at least one comorbidity (e.g. cardiovascular or chronic pulmonary disease) has been reported in 60% to 90% of hospitalized COVID-19 patients [7]. Regarding access to care, a positive association between a long time interval between COVID-19 diagnosis or hospital admission and the occurrence of severe disease or death has been described but little data are available [8, 9].

The NOSO-COR study is an international observational, prospective, multicentric study carried out in 13 French hospitals and hospitals affiliated with the GABRIEL network [10] in order to estimate the prevalence and incidence of SARS-CoV-2 infection and to assess the associated characteristics among healthcare workers and patients. Our previous results, based on 417 patients, showed that in COVID-19 patients, age as well as delay between symptom onset and hospital admission were both associated with ICU admission [11].

In order to investigate this observation further in a larger number of patients, this work aimed #1) to describe in detail the characteristics and symptoms of community-acquired (CA) COVID-19 patients at hospital admission according to the delay between symptom onset and hospital admission, #2) to identify determinants associated with the delay of admission.

Methods
The present work was restricted to patients with CA SARS-CoV-2 infection admitted to Lyon University Hospitals (Hospices Civils de Lyon, HCL), between February 8 and June 30, 2020 with complete data at discharge or death. Compared to our previously published work [11], this analysis was based on the same cohort, but with a larger number of patients (n = 827 versus n = 417 in the previously published paper).

The detailed protocol of the NOSO-COR study is available online [10]. Briefly, any patient who presented an infectious syndrome based on the WHO definition of COVID-19 as of March 30, 2020 [12], and was hospitalized for a period of at least 24 hours, was included. Patients with positive real-time Reverse Transcriptase–Polymerase Chain Reaction (RT-PCR) results were defined as laboratory confirmed SARS-CoV-2 infections. A CA SARS-CoV-2 infection was defined as a patient with symptom onset before or at hospital admission.
Demographic characteristics, underlying comorbidities, clinical and biological parameters and patient outcome data were collected. The clinical outcomes were monitored up to hospital discharge or in-hospital death.

Delay between symptom onset and hospital admission was computed as the difference between the two dates. Data higher than the 99th percentile of the distribution of the delay were considered as outliers and removed. We categorized the delay in 2 groups according to the median of its distribution: “Short delay” when occurrence of symptoms was 5 days (included) or less before hospital admission; “long delay” when occurrence of symptoms was ≥6 days before hospital admission. This choice was guided by the distribution of the variable (S1 Fig and S1 Table). Admission to ICU included patients directly admitted to ICU and those hospitalized in a medical ward and subsequently transferred to ICU during their hospitalization. Continuous variables were reported as median and interquartile range (IQR) with comparisons using the Mann-Whitney U test. Qualitative variables were computed as number of individuals (n) and frequency (%) using the χ2 or Fisher exact test as appropriate for comparison. The trend of the delay between symptom onset and hospital admission by age group and the trend of the proportion of patients with ICU hospitalization by age group were assessed using Cuzick’s test. All tests were 2-tailed, with p<0.05 considered statistically significant.

The logistic regression analysis was performed with delay between symptom onset and hospital admission as the dependent variable. Explanatory variables were first tested by univariate regression. Interaction of each variable with the variable age ≥75 years and sex was tested 1 by 1. Variables with p<0.10 in univariate analysis were added in a multivariate logistic regression model (i.e. the complete model). Then, using a backward selection technique, variables were removed one by one from the complete model, in order to keep the simplest model to predict the delay (i.e. the parsimonious model). Holmes correction for multiple testing was applied to the final parsimonious model. Statistical analysis was performed using STATA 13le (College Station, TX, USA).

Ethics
The study was approved by the clinical research and ethics committee of Ile-de-France V on March 8, 2020 (NOSO-COR, ClinicalTrials: NCT04290780). This study is an observational study based on patient medical records, and all data were fully anonymized at the time of collection. According to French law, patients or parents/guardians of minors received written information on this observational study, and their non-opposition to the use of their data was obtained.

Results
Between February 8 and June 30, 2020, a total of 1,150 patients hospitalized in Lyon University Hospital were included. Of the 905 (78.7%) patients with a CA SARS-CoV-2 infection, 67 (7.4%) were excluded because of an unknown delay between symptom onset and hospital admission, and 11 (1.2%) were considered as outliers, leaving 827 patients for the final analysis.

The characteristics of the overall study population, according to the delay between symptom onset and hospital admission, are detailed in Table 1. The median age was 73 years (IQR: 61–84), 55.9% of patients were male, 21.9% were admitted to intensive care unit (ICU) or transferred to ICU during their hospitalization. Cardiovascular disease was the most frequent comorbidity (53.2%). Patients with a longer delay were younger (p<0.01); had a higher body mass index (p<0.01); were more frequently admitted to ICU (p<0.01). They presented different characteristics and symptoms at admission more frequently, particularly cough (p<0.01),
Table 1. Characteristics of the study population according to delay between symptom onset and hospital admission, Lyon University Hospital (NOSO-COR Study), February 8–June 30, 2020.

| Characteristics                                                                 | All patients n = 827 | Patient with a short delay between symptom onset and hospital admission (≤5 days): n = 421 | Patient with a long delay between symptom onset and hospital admission (≥6 days): n = 406 | p-value |
|---------------------------------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------|
| Male gender, n (%)                                                             | 462 (55.9)           | 219 (52.0)                                                                                  | 243 (59.9)                                                                                  | 0.02    |
| Age, median (IQR)                                                              | 73 (61–84)           | 79 (65–87)                                                                                  | 69 (54–78)                                                                                  | <0.01   |
| Age ≥ 75 y., n (%)                                                             | 384 (46.4)           | 246 (58.4)                                                                                  | 138 (34.0)                                                                                  | <0.01   |
| BMI, median (IQR)                                                              | 26.2 (23.1–29.7) [664]| 25.7 (22.5–29.2) [349]                                                                      | 26.7 (23.7–30.0) [315]                                                                      | <0.01   |
| BMI ≥ 30, n (%)                                                                | 153 (23.0)           | 76 (21.8)                                                                                   | 77 (24.4)                                                                                   | 0.42    |
| Comorbidities, n (%)                                                            |                      |                                                                                             |                                                                                             |         |
| Cardiovascular disease                                                         | 440 (53.2)           | 256 (60.8)                                                                                  | 184 (45.3)                                                                                  | <0.01   |
| Diabetes                                                                       | 191 (23.1)           | 106 (25.2)                                                                                  | 85 (20.9)                                                                                   | 0.15    |
| Malignancy                                                                      | 146 (17.7)           | 92 (21.9)                                                                                   | 54 (13.3)                                                                                   | 0.01    |
| Chronic kidney disease                                                         | 115 (13.9)           | 72 (17.1)                                                                                   | 43 (10.6)                                                                                   | 0.07    |
| Chronic lung disease                                                           | 103 (12.5)           | 60 (14.3)                                                                                   | 43 (10.6)                                                                                   | 0.11    |
| Chronic liver disease                                                          | 55 (7.5) [736]       | 28 (7.1) [395]                                                                              | 27 (7.9) [341]                                                                              | 0.67    |
| Immunodeficiency                                                               | 48 (5.8)             | 27 (6.4)                                                                                   | 21 (5.2)                                                                                   | 0.45    |
| Smoking status, n (%)                                                           |                      |                                                                                             |                                                                                             |         |
| Current smoker                                                                  | 29 (4.6)             | 18 (5.9)                                                                                   | 11 (3.4)                                                                                   | 0.30    |
| Ex-smoker                                                                       | 197 (31.5)           | 97 (31.9)                                                                                  | 100 (31.1)                                                                                  |         |
| Never smoker                                                                    | 400 (63.9)           | 189 (62.2)                                                                                  | 211 (65.5)                                                                                  |         |
| Characteristics                                                                 |                      |                                                                                             |                                                                                             |         |
| Temperature at admission, median (IQR)                                         | 38.0 (37.1–38.6) [739]| 38.0 (37.2–38.5) [383]                                                                       | 38.0 (37.1–38.8) [356]                                                                       | 0.12    |
| Symptoms at admission, n (%)                                                   |                      |                                                                                             |                                                                                             |         |
| History of fever/chills                                                        | 674 (81.5)           | 330 (78.4)                                                                                  | 344 (84.7)                                                                                  | 0.02    |
| Weakness                                                                        | 584 (70.6)           | 282 (67.0)                                                                                  | 302 (74.4)                                                                                  | 0.02    |
| Cough                                                                           | 560 (67.7)           | 252 (59.9)                                                                                  | 308 (75.9)                                                                                  | <0.01   |
| Shortness of breath                                                             | 550 (66.5)           | 257 (61.1)                                                                                  | 293 (72.2)                                                                                  | 0.01    |
| Diarrhea                                                                        | 229 (27.8)           | 103 (24.5)                                                                                  | 126 (31.0)                                                                                  | 0.04    |
| Pain                                                                            | 225 (27.2)           | 97 (23.0)                                                                                   | 128 (31.5)                                                                                  | <0.01   |
| Myalgia                                                                         | 144 (17.4)           | 60 (14.3)                                                                                   | 84 (20.7)                                                                                   | 0.02    |
| Abdominal pain                                                                  | 62 (7.5)             | 36 (8.6)                                                                                   | 26 (6.4)                                                                                   | 0.24    |
| Chest pain                                                                      | 50 (6.0)             | 19 (4.5)                                                                                   | 31 (7.6)                                                                                   | 0.06    |
| Joint pain                                                                      | 12 (1.5)             | 5 (1.2)                                                                                   | 7 (1.7)                                                                                   | 0.99    |
| Nausea                                                                          | 107 (12.9)           | 50 (11.9)                                                                                  | 57 (14.0)                                                                                  | 0.35    |
| Headache                                                                        | 105 (12.7)           | 43 (10.2)                                                                                  | 62 (15.3)                                                                                  | 0.03    |
| Confusion                                                                       | 93 (11.3)            | 63 (14.5)                                                                                  | 30 (7.4)                                                                                   | 0.01    |
| Runny nose                                                                      | 72 (8.7)             | 33 (7.8)                                                                                   | 39 (9.6)                                                                                   | 0.37    |
| Ageusia                                                                         | 64 (7.7)             | 14 (3.3)                                                                                   | 50 (12.3)                                                                                  | <0.01   |
| Anosmia                                                                         | 58 (7.0)             | 12 (2.9)                                                                                   | 46 (11.3)                                                                                  | <0.01   |
| Sore throat                                                                     | 34 (4.1)             | 16 (3.8)                                                                                   | 18 (4.4)                                                                                   | 0.65    |
| Biological parameters, median (IQR)                                            |                      |                                                                                             |                                                                                             |         |
| White blood cells (G/L)                                                         | 6.36 (4.87–8.59) [769]| 6.46 (4.71–8.62) [394]                                                                       | 6.26 (4.95–8.52) [375]                                                                       | 0.76    |
| Neutrophils (G/L)                                                              | 4.75 (3.28–6.63) [768]| 4.73 (3.19–7.07) [393]                                                                       | 4.82 (3.35–6.61) [375]                                                                       | 0.69    |

(Continued)
weakness (p = 0.02), shortness of breath (p = 0.01), pain (p < 0.01), ageusia (p < 0.01) and anosmia (p < 0.01). The frequency of reported confusion was lower in patients with a longer delay (p < 0.01), whereas the plasmatic levels of C-reactive protein (CRP) were significantly higher (p < 0.01) than in patients with a shorter delay. The crude in-hospital fatality rate was lower in the group of patients with a longer delay (13.3%) than in patients with a short delay (27.6%), p < 0.01.

Median delay between symptom onset and hospital admission was 5 days (IQR: 3–9). This delay was significantly longer in ICU-hospitalized patients compared to those without ICU admission (7 days [IQR: 4–10] vs 5 days [IQR: 2–8], p < 0.01).

As shown in Fig 1, the delay between symptom onset and hospital admission and the proportions of patients hospitalized to ICU decreased with age for patients above 60 years of age (p < 0.01 and p < 0.01, respectively). Patient characteristics according to age are displayed in S2 Table. The results showed that the median delay between symptom onset and hospital admission decreased in older patients (P < 0.01). The proportion of ICU admission decreased in older patients (P < 0.01), while death during hospitalization increased in this population (P < 0.01). Overall, older patients had more comorbidities, such as cardiovascular diseases (P < 0.01), malignancy (P < 0.01) or chronic kidney diseases (P < 0.01) compared to younger patients.

Overall, 711 patients (86.0%) for whom complete data were available, were included in the logistic regression analysis. Table 2 depicts the association between underlying comorbidities, clinical features and biological parameters at admission and the delay between symptom onset and hospitalization. In multivariate analysis, age ≥ 75 years (p < 0.01), and confusion at admission (p = 0.02), were associated with a short delay between symptom onset and hospital admission. On the contrary, weakness (p = 0.02), cough (p = 0.01), ageusia (p = 0.02), anosmia (p = 0.03) and CRP > 100 mg/L at admission (p < 0.01) were associated with a long delay between symptom onset and hospital admission. After correction for multiple testing, only two variables remained significant in the model: age ≥ 75 years was associated with a short delay between symptom onset and hospital admission (p < 0.01) and CRP > 100 mg/L at admission was associated with a long delay between symptom onset and hospital admission (p < 0.01).

**Discussion**

The results of our study showed that during the course of SARS-CoV-2 infection, older patients (≥ 75 years) present earlier to the hospital. An association between younger age and

---

**Table 1. (Continued)**

| Lymphocytes (G/L) | 0.95 (0.64–1.31) [767] | 0.95 (0.63–1.32) [392] | 0.94 (0.64–1.30) [375] | 0.78 |
|-------------------|------------------------|------------------------|------------------------|------|
| CRP (mg/L)        | 71.4 (30.0–135.1) [711] | 65.0 (27.3–116.7) [369] | 86.6 (32.4–142.2) [342] | < 0.01 |
| Admission to ICU, n (%) | 181 (21.9) [767] | 76 (18.1) [392] | 105 (25.9) [375] | < 0.01 |
| Admission directly to ICU | 136 (16.4) [711] | 46 (10.9) [369] | 90 (22.2) [342] | < 0.01 |
| Admission to general ward and transfer to ICU during hospitalization | 45 (5.4) [767] | 30 (7.1) [392] | 15 (3.6) [375] | 0.03 |
| Death during hospitalization, n (%) | 170 (20.6) [767] | 116 (27.6) [392] | 54 (13.3) [375] | < 0.01 |

NOTE: in square brackets [:] number of data available for the variable. If no square brackets, there is no missing data for the variable. BMI: Body mass index, CRP: C-reactive protein, IQR: Interquartile range. *reference category: white blood cells ≤ 10 G/L, †reference category: Neutrophils ≤ 7.5 G/L, ‡reference category: Lymphocytes ≥ 1 G/L, §reference category: CRP ≤ 100 mg/L.

[https://doi.org/10.1371/journal.pone.0261428.t001](https://doi.org/10.1371/journal.pone.0261428.t001)
longer delay to hospital admission was also found in Brazil [13]. Higher prevalence of some infectious diseases (e.g. bacteremia) together with more severe presentation of other infectious diseases such as influenza in the elderly could explain, at least partly, the observed shorter delay between symptom onset and hospital admission in this population [14]. Aging plays a role in the pathogenic process and is also an independent determinant of outcome [11, 13]. However, age could also be a determinant of behavior and perception of risk and severity. A recent review of the literature showed that risk perception increases with age [15]. Some researchers even postulate the existence of “a unique integrated compensatory biological/behavioral immune system” by reasoning that the weakened immune system in older adults could be compensated by more prudent behavior [16, 17]. Age would therefore play a key role in the delay of access to care and the prognosis of COVID-19. It suggests also that young people without comorbidities may neglect the first clinical signs of COVID-19 and the need to consult health care facilities. Indeed, due to the widespread information communicated by social media on the low COVID-19 morbidity and mortality in this population; adolescents and young adults may have a lower risk perception of COVID-19 for themselves compared to older people, thus delaying the seeking of care [18–20].

A recent study carried out in China showed a positive association between severity of COVID-19 and the interval between symptom onset and diagnosis [9]. Similarly, the low
Table 2. Association between patient characteristics and delay between symptom onset and hospital admission, Lyon University Hospital (NOSO-COR Study), February 8–June 30, 2020.

| Characteristics                        | Crude OR of the risk of long delay between symptom onset and hospital admission (CI 95%) | p-value | Adjusted OR of the risk of long delay between symptom onset and hospital admission (>5 d) (ie. complete model) (CI 95%) | p-value | Adjusted OR of the risk of long delay between symptom onset and hospital admission (>5 d) (ie. parsimonious model) (CI 95%) | p-value | Corrected p-value (Holmes multiple testing correction) |
|----------------------------------------|------------------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------------------------|---------|--------------------------------------------------------|
| Male gender                            | 1.31 (0.98–1.77)                                                                         | 0.07    | 0.90 (0.65–1.26)                                                                                                  | 0.55    | 0.47 (0.34–0.66)                                                                                                  | <0.01   | <0.01                                                  |
| Age ≥ 75 y                              | 0.36 (0.26–0.49)                                                                         | <0.01   | 0.54 (0.38–0.77)                                                                                                  | <0.01   | 0.47 (0.34–0.66)                                                                                                  | <0.01   | <0.01                                                  |
| BMI ≥ 30                                | 1.17 (0.79–1.74)                                                                         | 0.43    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Comorbidities                           |                                                                                         |         |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Cardiovascular disease                  | 0.53 (0.39–0.72)                                                                         | <0.01   | 0.79 (0.56–1.11)                                                                                                  | 0.18    |                                                                                                                  |                                                   |                                                        |
| Diabetes                                | 0.90 (0.63–1.27)                                                                         | 0.55    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Malignancy                              | 0.55 (0.37–0.82)                                                                         | <0.01   | 0.66 (0.43–1.01)                                                                                                  | 0.06    | 0.65 (0.42–0.99)                                                                                                  | 0.05    | 0.08                                                   |
| Chronic lung disease                    | 0.73 (0.47–1.14)                                                                         | 0.16    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Chronic kidney disease                  | 0.61 (0.39–0.94)                                                                         | 0.03    | 0.93 (0.57–1.51)                                                                                                  | 0.76    |                                                                                                                  |                                                   |                                                        |
| Chronic liver disease                   | 1.13 (0.63–2.03)                                                                         | 0.69    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Immunodeficiency                        | 0.79 (0.41–1.50)                                                                         | 0.47    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Smoking status                          |                                                                                         |         |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Current smoking                         | 1 (ref.)                                                                                 |         |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Ex smoker                               | 1.52 (0.67–3.47)                                                                         | 0.32    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Never smoking                           | 1.53 (0.69–3.40)                                                                         | 0.29    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Symptoms at admission                   |                                                                                         |         |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| History of fever/chills                 | 1.57 (1.07–2.30)                                                                         | 0.02    | 1.28 (0.83–1.95)                                                                                                  | 0.26    |                                                                                                                  |                                                   |                                                        |
| Weakness                                | 1.40 (1.01–1.95)                                                                         | 0.04    | 1.52 (1.06–2.18)                                                                                                  | 0.02    | 1.53 (1.07–2.19)                                                                                                  | 0.02    | 0.08                                                   |
| Cough                                   | 2.13 (1.54–2.96)                                                                         | <0.01   | 1.47 (1.03–2.10)                                                                                                  | 0.03    | 1.56 (1.10–2.22)                                                                                                  | 0.01    | 0.08                                                   |
| Shortness of breath                     | 1.51 (1.10–2.06)                                                                         | 0.01    | 1.20 (0.84–1.70)                                                                                                  | 0.31    |                                                                                                                  |                                                   |                                                        |
| Diarrhea                                | 1.45 (1.04–2.01)                                                                         | 0.03    | 1.22 (0.85–1.75)                                                                                                  | 0.28    |                                                                                                                  |                                                   |                                                        |
| Myalgia                                 | 1.83 (1.24–2.69)                                                                         | <0.01   | 1.38 (0.89–2.13)                                                                                                  | 0.15    |                                                                                                                  |                                                   |                                                        |
| Abdominal pain                          | 0.83 (0.48–1.43)                                                                         | 0.50    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Chest pain                              | 1.60 (0.86–2.98)                                                                         | 0.14    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Joint pain                              | 1.52 (0.48–4.84)                                                                         | 0.48    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Nausea                                  | 1.15 (0.75–1.75)                                                                         | 0.53    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Headache                                | 1.66 (1.07–2.57)                                                                         | 0.02    | 1.02 (0.62–1.69)                                                                                                  | 0.94    |                                                                                                                  |                                                   |                                                        |
| Confusion                               | 0.41 (0.25–0.68)                                                                         | <0.01   | 0.56 (0.33–0.96)                                                                                                  | 0.04    | 0.52 (0.31–0.89)                                                                                                  | 0.02    | 0.08                                                   |
| Runny nose                              | 1.39 (0.83–2.34)                                                                         | 0.22    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |
| Ageusia                                 | 5.06 (2.57–9.94)                                                                         | <0.01   | 2.58 (1.17–5.71)                                                                                                  | 0.02    | 2.61 (1.20–5.71)                                                                                                  | 0.02    | 0.08                                                   |
| Anosmia                                 | 5.03 (2.48–10.19)                                                                        | <0.01   | 2.28 (0.98–5.29)                                                                                                  | 0.06    | 2.50 (1.10–5.70)                                                                                                  | 0.03    | 0.08                                                   |
| Sore throat                             | 1.08 (0.51–2.30)                                                                         | 0.84    |                                                                                                                  |                                                   |                                                                                                                  |                                                   |                                                        |

(Continued)
fatality rate from COVID-19 in South Korea was attributed to a rapid presentation to health care facilities as soon as symptoms appeared [21]. This observation has also been reported for other viral respiratory diseases, such as influenza, where more severe clinical presentation with admission to ICU have been associated to late laboratory diagnosis [22]. This work showed that a long delay between symptom onset and hospital admission was associated with an increase in ICU admission. However, it showed also that patient characteristics (e.g. age, comorbidities such as cardiovascular diseases) changed according to the delay between symptom onset and hospital admission, and could act as confounding factors. Indeed, the differences in patient characteristics, biological signs or imaging procedures, in particular age, inflammatory levels, or computed tomography detected lung lesions according to the delay between symptom onset and hospital admission have been reported to be closely linked to the clinical course of the disease and the prognosis [23, 24]. Investigating the association between delay of hospital admission and ICU admission is complex in the context of our study because of the heterogeneity of the population, the close relationship between ICU admission, age and patient health conditions. In addition, it is known that the first wave of COVID-19 created overloads in the healthcare system due to the limited number of beds in ICU [25, 26]. Our data did not allow to investigate whether the lower proportion of ICU admission in older patients was the result of or the presence of a large proportion of patients with do-not-resuscitate decisions.

Plasmatic level of CRP>100 mg/L was found to be associated with a long delay between symptom onset and hospital admission. It is known that hyper inflammation can occur during the clinical course of the disease [27] and that elevated plasmatic level of inflammatory biomarkers (such as CRP) were associated with COVID-19 severity [28]. Our results showed that clinical presentation at admission could be associated with the delay between symptom onset and hospital admission, even if the variables did not reach significance after correction for multiple testing (p = 0.08). Confusion at admission tended to be associated with a short delay between symptom onset and hospital admission, as already reported in the literature [29]. This observation could be explained by an early COVID-19 diagnosis and hospital admission in cognitively impaired persons, for example institutionalized persons or individuals with dementia [30]. Ageusia and anosmia tended to be associated with a long delay between symptom onset and hospital admission, whilst they are typically early symptoms [31]. A classification bias might explain this observation, as these two symptoms have a long time of recovery, up to several weeks [31].

Table 2. (Continued)

|                  | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
| White blood cells > 10 G/L | 0.86 (0.57–1.30) | 0.48                  |
| Neutrophils > 7.5 G/L         | 0.88 (0.60–1.31) | 0.54                  |
| Lymphocytes < 1 G/L           | 1.10 (0.82–1.48) | 0.51                  |
| CRP > 100 mg/L               | 1.72 (1.27–2.33) | <0.01                 |

NOTE: BMI: Body mass index, CRP: C-reactive protein

a in univariate analysis,
b in multivariate analysis, the complete model included all variables with p<0.10 in univariate analysis,
c in multivariate analysis, the model included the variables retained after backward selection, ie. age ≥75 y. o., malignancy, weakness, cough, confusion, ageusia, anosmia and CRP > 100 mg/L

https://doi.org/10.1371/journal.pone.0261428.t002
None of the studied comorbidities was associated with the delay between symptom onset and hospital admission, despite a statistical significance of cardiovascular diseases, malignancy, chronic kidney diseases in univariate analysis. These factors, described as risk factors for COVID-19 severity in other studies [32–34] are closely associated with age, which seems to be the major determinant of the delay between symptom onset and hospital admission.

The prospective character of the study design and data collection using a standardized protocol are the main strengths of the study implemented early in the pandemic. The study could bring additional findings that will inspire future exploration of the complex link between patient characteristics, delay of hospital admission and outcome for this emerging infection.

This study has however some limitations. We did not collect parameters such as socioeconomic status, known to be associated with access to care for other diseases [21]. Also, a bias might exist as governmental guidelines changed from March 2020 and during the entire COVID-19 pandemic, the French government recommended the general population to first call their general practitioner (GP) in case of suspicion of COVID-19. GPs had to prescribe nasopharyngeal swabs for COVID-19 confirmation, to assess the clinical severity of the COVID-19 confirmed patients and to call the emergency department to inform the hospital for those requiring hospitalization. Finally, the statistical power of the study could be too low to detect an independent effect between delay of hospital admission and patient characteristics.

In conclusion, delay between symptom onset and hospital admission is a key issue regarding prognosis. It can be related to individual characteristics, organization of care and/or a pathogenic process increasing the need for healthcare (e.g. exacerbation of a chronic disease). The respective contribution of these factors remains challenging to determine. Improving access to diagnosis, clinical surveillance and access to care after symptom onset is essential to avoid severe clinical symptoms in patients with high risk of severe disease. It could also reduce the rate of transmission during the interval between symptom onset and hospital admission, particularly in patients with a delayed diagnosis (e.g. young patients), by informing them about the prevention measures to apply. In this context, patient surveillance using a telemedicine system could be an innovative approach [35].

Supporting information
S1 Fig. Distribution of the variable “delay between symptom onset and hospital admission”.
(DOCX)

S1 Table. Characteristics of the study population according to the quartiles of delay between symptom onset and hospital admission, Lyon University Hospital (NOSO-COR Study), February 8–June 30, 2020.
(DOCX)

S2 Table. Characteristics of the study population according to age group, Lyon University Hospital (NOSO-COR Study), February 8–June 30, 2020.
(DOCX)

S1 File. Minimal underlying dataset.
(XLSX)

Acknowledgments
The authors express their gratitude to: COVID-Outcomes-HCL Consortium (affiliation for all: Hospices Civils de Lyon): Laurent Argaud, Frédéric Aubrun, Marc Bonnefoy, Maude
Author Contributions

Conceptualization: Philippe Vanhems.

Data curation: Christelle Elias, Séllalah Amour, Elisabetta Kuczewski, Mitra Saadatian-Elahi.

Formal analysis: Cédric Dananche, Marie-Paule Gustin.

Funding acquisition: Philippe Vanhems.

Investigation: Laetitia Hénaff, Séllalah Amour, Elisabetta Kuczewski, Vanessa Escuret.

Methodology: Cédric Dananche, Christelle Elias, Laetitia Hénaff, Vanessa Escuret, Mitra Saadatian-Elahi, Philippe Vanhems.

Project administration: Laetitia Hénaff, Mitra Saadatian-Elahi, Philippe Vanhems.

Resources: Mitra Saadatian-Elahi, Philippe Vanhems.

Supervision: Mitra Saadatian-Elahi, Philippe Vanhems.

Validation: Cédric Dananche, Christelle Elias, Laetitia Hénaff, Marie-Paule Gustin.

Visualization: Cédric Dananche, Christelle Elias, Séllalah Amour, Marie-Paule Gustin, Mitra Saadatian-Elahi, Philippe Vanhems.

Writing – original draft: Cédric Dananche, Mitra Saadatian-Elahi, Philippe Vanhems.

Writing – review & editing: Cédric Dananche, Christelle Elias, Laetitia Hénaff, Séllalah Amour, Elisabetta Kuczewski, Marie-Paule Gustin, Vanessa Escuret, Mitra Saadatian-Elahi, Philippe Vanhems.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382: 727–733. https://doi.org/10.1056/NEJMoa2001017 PMID: 31978945

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076

3. Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020; 65: 533–546. https://doi.org/10.1007/s00038-020-01390-7 PMID: 32451563

4. Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77
studies and 38,000 patients. PLoS One. 2020; 15: e0243191. https://doi.org/10.1371/journal.pone.0243191 PMID: 33284825

5. Sattar N, McNees IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020; 142: 4–6. https://doi.org/10.1161/CIRCULATIONAHA.120.047659 PMID: 32320270

6. Gao Y-D, Ding M, Dong X, Zhang J-J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021; 76: 428–455. https://doi.org/10.1111/all.14657 PMID: 33185910

7. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324: 782–793. https://doi.org/10.1001/jama.2020.12839 PMID: 32648899

8. Alaa A, Qian Z, Rashbash J, Benger J, van der Schaar M. Retrospective cohort study of admission timing and mortality following COVID-19 infection in England. BMJ Open. 2020; 10: e042712. https://doi.org/10.1136/bmjopen-2020-042712 PMID: 33234660

9. Li L, Sun W, Han M, Ying Y, Wang Q. A Study on the Predictors of Disease Severity of COVID-19. Med Sci Monit. 2020; 26: e927167. https://doi.org/10.12659/MSM.927167 PMID: 32963215

10. Saadatian-Eliahi M, Picot V, Henaff L, Pradel FK, Escuret V, Danančé C, et al. Protocol for a prospective, observational, hospital-based multicentre study of nosocomial SARS-CoV-2 transmission: NOSOCOR Project. BMJ Open. 2020; 10: e039088. https://doi.org/10.1136/bmjopen-2020-039088 PMID: 33093033

11. Vanhems P, Gustin M-P, Elias C, Henaff L, Danančé C, Grisi B, et al. Factors associated with admission to intensive care units in COVID-19 patients in Lyon-France. PLoS One. 2021; 16: e0243709. https://doi.org/10.1371/journal.pone.0243709 PMID: 33503018

12. World Health Organisation. Coronavirus disease 2019 (COVID-19) Situation Report-70. Page 9. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_2

13. de Cobre AF, Böger B, Fachi MM, de Vilhena RO, Domingos EL, Tonin FS, et al. Risk factors associated with delay in diagnosis and mortality in patients with COVID-19 in the city of Rio de Janeiro, Brazil. Cien Saude Colet. 2020; 25: 4131–4140. https://doi.org/10.1590/1413-812320202510.2.26882020 PMID: 33027349

14. Gavazzi G, Krause K-H. Ageing and infection. Lancet Infect Dis. 2002; 2: 659–666. https://doi.org/10.1016/s1473-3099(02)00437-1 PMID: 12409046

15. Tagini S, Brugnera A, Ferrucci R, Mazzocco K, Compare A, Silani V, et al. It won’t happen to me! Psychosocial factors influencing risk perception for respiratory infectious diseases: A scoping review. Appl Psychol Health Well Being. 2021. https://doi.org/10.1111/aphw.12274 PMID: 33855817

16. Diaz A, Beleña Á, Zueco J. The Role of Age and Gender in Perceived Vulnerability to Infectious Diseases. Int J Environ Res Public Health. 2020; 17: E485. https://doi.org/10.3390/ijerph17020485 PMID: 31940870

17. Gangestad SW, Grebe NM. Pathogen avoidance within an integrated immune system: Multiple components with distinct costs and benefits. Evol Behav Sci. 2014; 8(4), 226–234. https://doi.org/10.1037/ebis0000023

18. Reniers RLEP, Murphy L, Lin A, Bartolomé SP, Wood SJ. Risk Perception and Risk-Taking Behaviour during Adolescence: The Influence of Personality and Gender. PLoS One. 2016; 11: e0153842. https://doi.org/10.1371/journal.pone.0153842 PMID: 27100081

19. Yang XY, Gong RN, Sassine S, Morsa M, Tchogna AS, Drouin O, et al. Risk Perception of COVID-19 Infection and Adherence to Preventive Measures among Adolescents and Young Adults. Children. 2020; 7: 311. https://doi.org/10.3390/children7120311 PMID: 33371272

20. Barber SJ, Kim H. COVID-19 Worries and Behavior Changes in Older and Younger Men and Women. J Gerontol B Psychol Sci Soc Sci. 2021; 76: e17–e23. https://doi.org/10.1093/geronb/gbaa068 PMID: 32427341

21. Na BJ, Park Y, Huh IS, Kang CR, Lee J, Lee JY. Seventy-two Hours, Targeting Time from First COVID-19 Symptom Onset to Hospitalization. J Korean Med Sci. 2020; 35. https://doi.org/10.3346/jkms.2020.35.e192 PMID: 32449328

22. Choi S-H, Chung J-W, Kim T, Park K-H, Lee MS, Kwak YG. Late diagnosis of influenza in adult patients during a seasonal outbreak. Korean J Intern Med. 2018; 33: 391–396. PMID: 29177669

23. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020; 11: 4968. https://doi.org/10.1038/s41467-020-18786-x PMID: 33009413
24. Ruch Y, Kaeuffer C, Ohana M, Labani A, Fabacher T, Bilbault P, et al. CT lung lesions as predictors of early death or ICU admission in COVID-19 patients. Clin Microbiol Infect. 2020; 26: 1417.e5–1417.e8. https://doi.org/10.1016/j.cmi.2020.07.030 PMID: 32717417

25. Boëlle P-Y, Delory T, Maynadier X, Janssen C, Piarroux R, Pichonot M, et al. Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France. J Clin Med. 2020; 9: E3148. https://doi.org/10.3390/jcm9103148 PMID: 33003375

26. Flaatten H, Van Heerden V, Jung C, Beil M, Leaver S, Rhodes A, et al. The good, the bad and the ugly: pandemic priority decisions and triage. J Med Ethics. 2020; medethics-2020-106489. https://doi.org/10.1136/medethics-2020-106489 PMID: 32522814

27. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant. 2020; 39: 405–407. https://doi.org/10.1016/j.healun.2020.03.012 PMID: 32362390

28. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021; 26: 107–108. https://doi.org/10.1136/bmjebm-2020-111536 PMID: 32934000

29. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020; 41: 1667–1671. https://doi.org/10.1007/s10072-020-04486-3 PMID: 32483687

30. Vrillon A, Mhanna E, Aveneau C, Lebozec L, Grosset L, Nankam D, et al. COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients. Alzheimers Res Ther. 2021; 13: 77. https://doi.org/10.1186/s13195-021-00820-9 PMID: 33838684

31. Printza A, Katotomichelakis M, Metallidis S, Panagopoulos P, Sarafidou A, Petrakis V, et al. The clinical course of smell and taste loss in COVID-19 hospitalized patients. Hippokratia. 2020; 24: 66–71. PMID: 33488054

32. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10: 783–791. https://doi.org/10.1158/2159-8290.CD-20-0422 PMID: 32345594

33. Yanover C, Mizrahi B, Kalkstein N, Marcus K, Akiva P, Barer Y, et al. What Factors Increase the Risk of Complications in SARS-CoV-2-Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization. JMIR Public Health Surveill. 2020; 6: e20872. https://doi.org/10.2196/20872 PMID: 32750009

34. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020; 13: 75. https://doi.org/10.1186/s13045-020-00907-0 PMID: 32522278

35. Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020; 382: 1679–1681. https://doi.org/10.1056/NEJMp2003539 PMID: 32160451